User contributions for EssiV
Jump to navigation
Jump to search
20 April 2012
- 13:2813:28, 20 April 2012 diff hist 0 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results →Role of participation in assessment
- 13:2613:26, 20 April 2012 diff hist +238 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results →Role of participation in assessment
- 13:2413:24, 20 April 2012 diff hist 0 N File:OIP-Fig1..JPG No edit summary current
- 13:1513:15, 20 April 2012 diff hist −1 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results →Conclusions
- 13:1513:15, 20 April 2012 diff hist +15,678 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results No edit summary
- 13:0413:04, 20 April 2012 diff hist +5,376 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results No edit summary
- 12:5912:59, 20 April 2012 diff hist +10,899 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results No edit summary
- 12:5312:53, 20 April 2012 diff hist −6 m Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results No edit summary
- 12:5312:53, 20 April 2012 diff hist +14,088 Nm Openness in participation, assessment, and policy making upon issues of environment and environmental health: a review of literature and recent project results Created page with "{{nugget |authors= Mikko V. Pohjola, Jouni T. Tuomisto |reference= |urn= |ethics= |journal= |moderator= Essi Vuorinen |stub=}} This ..."
- 12:4112:41, 20 April 2012 diff hist 0 m State of the art in benefit–risk analysis: Economics and Marketing-Finance No edit summary current
- 12:4012:40, 20 April 2012 diff hist 0 m State of the art in benefit–risk analysis: Medicines No edit summary current
- 12:4012:40, 20 April 2012 diff hist −1 m State of the art in benefit–risk analysis: Food microbiology No edit summary
- 12:3812:38, 20 April 2012 diff hist +26 m State of the art in benefit–risk analysis: Food microbiology No edit summary
- 12:3712:37, 20 April 2012 diff hist +13 State of the art in benefit–risk analysis: Food microbiology No edit summary
- 12:3712:37, 20 April 2012 diff hist +83 m State of the art in benefit–risk analysis: Food microbiology No edit summary
- 12:3412:34, 20 April 2012 diff hist +2 m State of the art in benefit–risk analysis: Food microbiology →Benefit–risk assessment
- 12:3312:33, 20 April 2012 diff hist −2 m State of the art in benefit–risk analysis: Food microbiology →Benefit–risk assessment
- 12:3212:32, 20 April 2012 diff hist 0 m State of the art in benefit–risk analysis: Food microbiology →Benefit–risk assessment
- 12:3112:31, 20 April 2012 diff hist +4,221 m State of the art in benefit–risk analysis: Food microbiology →Benefit–risk assessment
- 12:2212:22, 20 April 2012 diff hist −1,825 m State of the art in benefit–risk analysis: Food microbiology →BRA scenarios in food microbiology
- 12:1912:19, 20 April 2012 diff hist +1 m State of the art in benefit–risk analysis: Food microbiology →BRA scenarios in food microbiology
- 12:1912:19, 20 April 2012 diff hist +73 m State of the art in benefit–risk analysis: Food microbiology →BRA scenarios in food microbiology
- 12:1912:19, 20 April 2012 diff hist +2 m State of the art in benefit–risk analysis: Food microbiology →BRA scenarios in food microbiology
- 12:1612:16, 20 April 2012 diff hist +1,749 m State of the art in benefit–risk analysis: Food microbiology →BRA scenarios in food microbiology
- 12:0812:08, 20 April 2012 diff hist +45,225 Nm State of the art in benefit–risk analysis: Food microbiology Created page with "{{nugget |authors=S.H. Magnússon, H. Gunnlaugsdóttir, H. van Loveren, F. Holm, N. Kalogeras, O. Leino, J.M. Luteijn, G. Odekerken, Mikko V. Pohjola, M.J...."
- 11:5011:50, 20 April 2012 diff hist −2 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Authors and contact information
- 11:5011:50, 20 April 2012 diff hist +22 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Authors and contact information
- 11:3811:38, 20 April 2012 diff hist +67 m State of the art in benefit–risk analysis: Economics and Marketing-Finance No edit summary
- 11:2911:29, 20 April 2012 diff hist +8 m State of the art in benefit–risk analysis: Economics and Marketing-Finance No edit summary
19 April 2012
- 23:1423:14, 19 April 2012 diff hist −2 m State of the art in benefit–risk analysis: Medicines →References
- 23:1023:10, 19 April 2012 diff hist −1 m State of the art in benefit–risk analysis: Medicines →References
- 23:0623:06, 19 April 2012 diff hist −3 m State of the art in benefit–risk analysis: Medicines →References
- 23:0423:04, 19 April 2012 diff hist −1 m State of the art in benefit–risk analysis: Medicines →The benefit–risk monitoring process
- 23:0323:03, 19 April 2012 diff hist +31 m State of the art in benefit–risk analysis: Medicines No edit summary
- 22:5022:50, 19 April 2012 diff hist +243 m State of the art in benefit–risk analysis: Medicines →Drug discovery and development
- 22:4322:43, 19 April 2012 diff hist +7 m State of the art in benefit–risk analysis: Medicines →References
- 22:3722:37, 19 April 2012 diff hist +23 m State of the art in benefit–risk analysis: Medicines →References
- 22:3222:32, 19 April 2012 diff hist +24 m State of the art in benefit–risk analysis: Medicines →References
- 22:2922:29, 19 April 2012 diff hist −28 m State of the art in benefit–risk analysis: Medicines →References
- 22:2222:22, 19 April 2012 diff hist +43,020 m State of the art in benefit–risk analysis: Medicines No edit summary
- 21:5421:54, 19 April 2012 diff hist +2 m State of the art in benefit–risk analysis: Medicines No edit summary
- 21:5321:53, 19 April 2012 diff hist +2,435 Nm State of the art in benefit–risk analysis: Medicines Created page with "{{nugget |authors= |reference= |urn= |ethics= |journal= |moderator= EssiV |stub=}} This page (including the files available for download at the bottom of this page) contai..."
- 21:2321:23, 19 April 2012 diff hist 0 N File:Medicines-Fig1jj.jpg No edit summary current
- 15:1715:17, 19 April 2012 diff hist +249 m State of the art in benefit–risk analysis: Economics and Marketing-Finance No edit summary
- 15:1215:12, 19 April 2012 diff hist −1 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Utility elicitation techniques
- 15:1115:11, 19 April 2012 diff hist +1 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Utility elicitation techniques
- 15:1115:11, 19 April 2012 diff hist +97 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →The CE technique
- 15:1015:10, 19 April 2012 diff hist +579 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Utility elicitation techniques
- 15:0915:09, 19 April 2012 diff hist −678 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →The EU approach
- 15:0715:07, 19 April 2012 diff hist 0 m State of the art in benefit–risk analysis: Economics and Marketing-Finance →Utility functional forms
